Seeking Alpha
 

Baxter International Inc (BAX)

- NYSE
  • Jul. 22, 2014, 9:03 AM
    • Baxter International (NYSE:BAX) declares $0.52/share quarterly dividend, in line with previous.
    • Forward yield 2.73%
    • Payable Oct. 1; for shareholders of record Sept. 5; ex-div Sept. 3.
    | Comment!
  • Jul. 17, 2014, 8:10 AM
    • Baxter International (NYSE:BAX) Q2 results: Total Revenues: $4,264M (+16.2%); BioScience: $1,751M (+6.9%); Medical Products: $2,513M (+23.7%).
    • Bioscience Revenues: Hemophilia: $904M (+6.5%); BioTherapeutics: $548M (+6.8%); BioSurgery: $189M (+6.2%); Vaccines: $110M (+12.2%).
    • Medical Products Revenues: Fluid Systems: $816M (+8.1%); Renal: $1,044M (+59.6%); Specialty Pharma: $404M (+10.4%); BioPharma Solutions: $249M (-2.7%).
    • COGS: $2,041M (+5.3%); R&D Expense: $325M (+19.0%); SG&A Expense: $998M (+19.1%); Net Income: $520M (-11.9%); EPS: $0.95 (-11.2%); CF Ops: $599M (-21.5%). Gross Profit: $2,041M (+5.3%); COGS: 52.1% (+10.6%); Gross Margin: 47.9% (-9.4%); Operating Profit: $718M (-13.3%); Operating Earnings Yield: 16.8% (-25.4%); Net Earnings Yield: 12.2% (-24.2%).
    • 2014 Guidance: Sales Growth: 10 - 11% up from 9 - 10%; EPS ex items: $5.10 - 5.20 versus $5.05 - 5.25; CF Ops: ~$3.5B (unch).
    • Press release
    | Comment!
  • Jul. 17, 2014, 7:04 AM
    • Baxter (NYSE:BAX): Q2 EPS of $1.26 beats by $0.04.
    • Revenue of $4.26B (+16.1% Y/Y) beats by $140M.
    • Press Release
    | Comment!
  • Jul. 16, 2014, 5:30 PM
  • Jul. 9, 2014, 9:16 AM
    • Baxter International (BAX) acquires AesRx LLC, a private biopharmaceutical company focused on orphan drug targets. Its lead product candidate, currently in Phase 2, is Aes-103 (5-hydroxymethylfurfural) a small molecule compound being investigated as a prophylactic treatment for sickle cell disease. Financial terms are not disclosed.
    | Comment!
  • Jul. 7, 2014, 9:51 AM
    • Baxter International (BAX +0.3%) CFO Robert J. Hombach departs to assume senior operational responsibilities at the recently-spun-out biopharmaceuticals business. He will report to CEO Ludwig N. Hantson, Ph.D. Former Baxter treasurer James K. Saccaro rejoins the firm as CFO from Hill-Rom where he was SVP and CFO.
    | Comment!
  • Jul. 1, 2014, 7:23 AM
    • CTI BioPharma (CTIC) completes enrollment in the PERSIST-1 Phase 3 clinical trial of pacritinib, an oral JAK2/FLT3 inhibitor being evaluated as a treatment for myelofibrosis. Under the terms of the development and commercialization agreement with Baxter International (BAX), CTI expects to receive a $20M milestone payment when the last patient in the trial begins dosing. The payment should occur this quarter.
    • There are approximately 320 patients enrolled in PERSIST-1. It is a randomized, open-label multicenter study comparing the safety and efficacy of pacritinib with best available therapy, other that JAK inhibitors, in patients with primary myelofibrosis without exclusion for low platelet counts. The primary endpoint is the percentage of patients achieving at least a 35% reduction in spleen volume measured by MRI or CT at 24 weeks of treatment.
    | 1 Comment
  • May. 19, 2014, 10:22 AM
    • The U.S. Supreme Court declines to hear an appeal by Baxter International (BAX -0.1%) in a dialysis machine patent suit with Fresenius Medical Care (FMS -0.7%). The issue is whether a court can throw out a patent infringement judgement in a case where the patent office decides that a patent is invalid while the litigation is in process. The court's action means that the July 2013 ruling by the U.S. Court of Appeals remains intact whereby it threw out a $24M judgment in favor of Baxter.
    • Biotech and pharma industry groups urged the court to hear the case because the appeals court ruling creates uncertainty due to the encouragement of time-wasting dual-track litigation.
    • Fresenius originally challenged the Baxter patent in 2003. Baxter counter-sued and won a judgement in 2012 that required the former to pay for infringement. During the litigation, Fresenius asked the patent office to reconsider the validity of the patent which it did in 2010.
    | Comment!
  • May. 5, 2014, 4:45 PM
    • Baxter International Inc (BAX) declares $0.52/share quarterly dividend, 6.1% increase from prior dividend of $0.49.
    • Forward yield 2.79%
    • Payable July 1; for shareholders of record June 6; ex-div June 4.
    | Comment!
  • Apr. 17, 2014, 8:58 AM
    • Q1 NI of $556M increased $4M (+0.7%) compared to Q1'13. NI ex-items was $652M up 8% from last year's $601M.
    • Total revenue for the quarter was $3.95B. Revenue ex-Gambro was $3.55B (+3%). Bioscience revenue was $1.61B (+5%). Medical Products revenue was $2.34B (+22%).
    • Q2 guidance calls for sales growth of 12% - 13% excluding foreign currency risk and EPS ex-items of $1.18 - $1.22.
    • 2014 guidance includes revenue growth of 9% - 10% ex foreign currency risk and EPS ex-items of $5.05 - $5.25.
    • (BAX)
    | Comment!
  • Apr. 17, 2014, 7:02 AM
    • Baxter (BAX): Q1 EPS of $1.19 beats by $0.11.
    • Revenue of $3.95B (+14.5% Y/Y) beats by $70M.
    • Press Release
    | Comment!
  • Apr. 17, 2014, 12:05 AM
  • Apr. 16, 2014, 5:30 PM
  • Apr. 16, 2014, 9:28 AM
    • Baxter International's (BAX) BAX 111 treatment met the primary endpoint in a Phase III trial of patients with von Willebrand disease, the most common type of inherited bleeding disorder.
    • BAX 111 successfully treated 22 patients who experienced bleeding episodes during the trial.
    • Secondary endpoints included those related to additional efficacy and safety measures, pharmacokinetics and health-related quality of life.
    • Shares are +1.55% premarket. (PR)
    | Comment!
  • Mar. 27, 2014, 9:11 AM
    | 2 Comments
  • Mar. 27, 2014, 8:08 AM
    • Baxter International (BAX) is splitting into two companies, with one focused on biopharmaceuticals and the other on medical products.
    • Baxter will make a tax-free distribution of shares in the biopharmaceuticals business to its shareholders. The company expects to complete the transaction by mid-2015.
    • The biopharmaceuticals business generated 2013 annual revenues of $6B and develops treatments for hemophilia and other bleeding disorders, immune deficiencies, burns and shock.
    • The medical-products business earned annual sales of over $9B and provides intravenous (IV) solutions and nutritional therapies, drug-delivery systems and administration sets, and premixed and other injectable drugs, as well as inhalation anesthetics and hospital-based biosurgery products.
    • Baxter CEO Robert Parkinson will head the medical-products company, which will retain the Baxter International name.
    • Ludwig Hantson, who is president of BioScience, will run the biopharmaceuticals firm. (PR)
    • Shares are +12.5%.
    | 15 Comments
Visit Seeking Alpha's
BAX vs. ETF Alternatives
Company Description
Baxter International Inc is a healthcare company. It develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions.